Aaron Kahlam, MD1, Alexander Le, MD1, Fredella Lee, MD2, Yazan Abboud, MD1, Ayham Khrais, DO1, Param Patel, MD1, David Kim, MD1, Sushil Ahlawat, MD, MS, MBBS3, Siddharth Verma, DO4, Daniel Matassa, MD1 1Rutgers New Jersey Medical School, Newark, NJ; 2New York-Presbyterian / Weill Cornell Medical Center, New York, NY; 3SUNY Downstate Health Sciences University, Brooklyn, NY; 4East Orange VA Medical Center, East Orange, NJ
Introduction: Colonoscopy is the gold standard for colon cancer screening. However, it is essential to have adequate bowel preparation, as poor preparation can increase the risk of missed adenomas, procedure time and aborted procedures. Previous studies have shown that methadone use increases the risk of poor preparation, however no studies have analyzed the effect buprenorphine may have on bowel preparation.
Methods: A retrospective chart review of patients with opioid use disorder at University Hospital in Newark, NJ who underwent colonoscopy from 2015-2022 was conducted. Patients with history of colon cancer, active gastrointestinal bleed, and without treatment for opioid use disorder were excluded. Procedure reports were used to identify the primary outcome (bowel preparation quality) and secondary outcomes (procedure time and aborted procedures). Additionally, demographic data, presence of a fellow, history of diabetes and gastroparesis were also collected as controls. Chi-squared and independent t-tests were used to compare means between categorical and continuous variables, respectively, and logistic regression was used to control for confounding variables.
Results: 70 charts were reviewed, of which 44 patients were taking buprenorphine and 26 were taking methadone. There was no significant difference in bowel preparation between patients taking buprenorphine compared to those taking methadone as treatment for their opioid use disorder. There was also no significant difference in procedure time between the two groups (24.0 minutes versus 25.4 minutes, p = 0.61). When controlling for presence of a fellow, diabetes and demographic variables, there was no significant difference in bowel preparation between patients taking buprenorphine compared to those taking methadone (p = 0.26). Finally, there was no significant difference in the number of aborted procedures between the two groups (p= 0.35).
Discussion: We found that patients taking buprenorphine had a similar bowel preparation quality to patients taking methadone for opioid use disorder. Additionally, there was no difference in secondary outcomes between the two groups. As patients with opioid use disorder age, it will be important to further understand the effects treatment may have on bowel preparation for colorectal cancer screening.
Note: The table for this abstract can be viewed in the ePoster Gallery section of the ACG 2024 ePoster Site or in The American Journal of Gastroenterology's abstract supplement issue, both of which will be available starting October 27, 2024.
Disclosures:
Aaron Kahlam indicated no relevant financial relationships.
Alexander Le indicated no relevant financial relationships.
Fredella Lee indicated no relevant financial relationships.
Yazan Abboud indicated no relevant financial relationships.
Ayham Khrais indicated no relevant financial relationships.
Param Patel indicated no relevant financial relationships.
David Kim indicated no relevant financial relationships.
Sushil Ahlawat indicated no relevant financial relationships.
Siddharth Verma indicated no relevant financial relationships.
Daniel Matassa indicated no relevant financial relationships.
Aaron Kahlam, MD1, Alexander Le, MD1, Fredella Lee, MD2, Yazan Abboud, MD1, Ayham Khrais, DO1, Param Patel, MD1, David Kim, MD1, Sushil Ahlawat, MD, MS, MBBS3, Siddharth Verma, DO4, Daniel Matassa, MD1. P3816 - The Impact of Buprenorphine Compared to Methadone on Bowel Preparation for Screening Colonoscopy, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.
